MAPK9: Mitogen-activated protein kinase 9
Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on MAPK9, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
| CC-401 | Phase 2 | Bristol-Myers Squibb | Small molecule | Inhibitorc-Jun N-terminal kinase 2 inhibitor | 0 |
| Tanzisertib | Phase 2 | Bristol-Myers Squibb | Small molecule | Inhibitorc-Jun N-terminal kinase 2 inhibitor | 0 |
- Cancer0.56
- Neoplasm0.10
- Discoid lupus erythematosus0.10
- Hepatocellular carcinoma0.10
- Abnormal central motor function0.09
- Idiopathic pulmonary fibrosis0.08
- Epidermolysis bullosa simplex 2E, with migratory circinate erythema0.08
- Breast carcinoma0.07
- Uncombable hair syndrome0.07
- Endometriosis0.07
- Oculocutaneous albinism type 60.07
- Hypotrichosis simplex0.07
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4179, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P45984, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets